Dow Down0.01% Nasdaq Down0.13%

Valeant Pharmaceuticals International, Inc. (VRX)

-NYSE
116.48 Down 0.62(0.53%) 3:25PM EDT - Nasdaq Real Time Price
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingDec 31, 2009Dec 31, 2008Dec 31, 2007
Total Revenue 830,461   656,977   872,222  
Cost of Revenue210,810  167,916  233,094  
Gross Profit 619,651   489,061   639,128  
Operating Expenses
Research Development43,977  86,967  98,025  
Selling General and Administrative262,133  278,019  371,045  
Non Recurring10,068  207,595  23,176  
Others70,640  49,973  71,567  
Total Operating Expenses386,818  622,554  563,813  
Operating Income or Loss 232,833   (133,493) 75,315  
Income from Continuing Operations
Total Other Income/Expenses Net10,087  7,637  18,852  
Earnings Before Interest And Taxes242,920  (125,856)94,167  
Interest Expense43,571  30,486  42,878  
Income Before Tax199,349  (156,342)51,289  
Income Tax Expense(58,270)33,913  25,233  
Minority Interest(3)(7)(2)
Net Income From Continuing Ops257,619  (190,262)26,054  
Non-recurring Events
Discontinued Operations6,125  166,548  (32,240)
Extraordinary Items -   -   -  
Effect Of Accounting Changes -   -   -  
Other Items -   -   -  
Net Income 263,741   (23,714) (6,186)
Preferred Stock And Other Adjustments -   -   -  
Net Income Applicable To Common Shares 263,741   (23,714) (6,186)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.